ライフサイエンスコーパス: graft-versus-leukemia effect

1 emonstrate which NK cell subsets mediate the graft versus leukemia effect.

2 ural killer (NK) cells, key effectors of the Graft versus Leukemia effect.

3 , while maintaining immunocompetence and the graft versus leukemia effect.

4 n clinical trials while maintaining a robust graft-versus-leukemia effect.

5 ct of CMV infection has been reported on the graft-versus-leukemia effect.

6 hematologic diseases, with an often critical graft-versus-leukemia effect.

7 a means of decreasing GVHD while retaining a graft-versus-leukemia effect.

8 egies to predict a dominant unit and enhance graft-versus-leukemia effect.

9 cell dose on relapse may represent a delayed graft-versus-leukemia effect.

10 due to allogeneic disparities enhancing the graft-versus-leukemia effect.

11 tion and expansion in vivo, while preserving graft-versus-leukemia effects.

12 of human GVHD while ensuring conservation of graft-versus-leukemia effects.

13 f NK-cell-dependent in vivo cytotoxicity and graft-versus-leukemia effects.

14 e, which may have important implications for graft-versus-leukemia effects.

15 ls is crucial for promoting NK cell-mediated graft-versus-leukemia effects.

16 r adult recipients or an effective level of "graft-versus-leukemia" effect.

17 vaccines represent a strategy to enhance the graft-versus-leukemia effect after allogeneic blood and

18 Despite observed graft-versus-leukemia effects after stem cell transplant

19 Through an immune-mediated graft-versus-leukemia effect, allogeneic hematopoietic s

20 g the late establishment of a posttransplant graft-versus-leukemia effect and an overrepresentation o

21 ice with the advantages of possible stronger graft-versus-leukemia effect and expanding transplantati

22 outcomes, results of nonmyeloablative UCBT, graft-versus-leukemia effect and graft-versus-host disea

23 CML in chronic phase, its responsiveness to graft-versus-leukemia effect and the ability to monitor

24 nistered after BMT might induce or amplify a graft-versus-leukemia effect and thereby reduce the rela

25 e development of new strategies to enhance a graft-versus-leukemia effect and to decrease the inciden

26 Whether such differences will compromise graft-versus-leukemia effects and disease-free survival

27 as GVHD prophylaxis, Tregs potently suppress graft-versus-leukemia effects and so may be most appropr

28 nefit, the value of purging, the presence of graft-versus-leukemia effect, and the timing of transpla

29 CLL is susceptible to graft-versus-leukemia effects, and allogeneic HCT after

30 The graft-versus-leukemia effect appeared effective, even in

31 elapse due to the lack of an immune-mediated graft-versus-leukemia effect, as occurs in the allogenei

32 al killer lymphocytes may play a role in the graft-versus-leukemia effect, attention is focusing incr

33 risk of early relapse/progression before the graft-versus-leukemia effect being disproportionally lar

34 or lymphocyte transfusions indicate that the graft-versus-leukemia effect can be very powerful and to

35 d fludarabine, relying almost exclusively on graft-versus-leukemia effects, can result in long-term r

36 In addition to providing a graft-versus-leukemia effect, donor T cells are critical

37 at mediate graft-versus-host disease and the graft-versus-leukemia effect following stem cell transpl

38 ractions between HLA-C and KIR might promote Graft-versus-Leukemia effects following transplantation.

39 g the beneficial graft-versus-tumor (GVT) or graft-versus-leukemia effects from graft-versus-host dis

40 new immunotherapeutic approach to separating graft-versus-leukemia effects from GvHD.

41 A graft-versus-leukemia effect has been well documented to

42 e immune system will allow us to improve the graft-versus-leukemia effect, improve engraftment, and d

43 apse risk, this analysis reveals an enhanced graft-versus-leukemia effect in acute leukemia patients

44 lapse responded, demonstrating a significant graft-versus-leukemia effect in CLL.

45 DR15 on graft-versus-host disease (GVHD) and graft-versus-leukemia effects in HLA-matched allogeneic

46 ells was associated with decreased cGVHD and graft-versus-leukemia effects in recipients of allogenei

47 The graft-versus-leukemia effect is critical to the maintena

48 The immune-mediated graft-versus-leukemia effect is important to prevent rel

49 ion for HLA-matched HCT may achieve superior graft versus leukemia effects, lower risk for relapse, a

50 tation can eradicate the leukemia and that a graft-versus-leukemia effect makes a major contribution

51 The graft-versus-leukemia effect of allogeneic stem-cell tra

52 MDSC-IL-13 did not reduce the graft-versus-leukemia effect of donor T cells.

53 ecipients was strikingly advantageous in the graft-versus-leukemia effects of delayed donor lymphocyt

54 monstration that an immunologically mediated graft-versus-leukemia effect plays a central role in del

55 of allogeneic cells and they rely largely on graft-versus-leukemia effects rather than high-dose cyto

56 The regimens rely largely on graft-versus-leukemia effects rather than high-dose ther

57 e after allografting; the mechanism for this graft-versus-leukemia effect remains speculative.

58 re has been a corresponding reduction in the graft-versus-leukemia effect so that any decrease in GVH

59 al in a mouse model of aGVHD while retaining graft-versus-leukemia effects, unveiling a novel therape

60 The graft-versus-leukemia effect was initially considered to

61 Although the graft-versus-leukemia effect was predicted from animal e

62 cross the placenta and might confer a potent graft-versus-leukemia effect when cord blood (CB) is use

63 inally, T-bet(-/-) T cells had a compromised graft-versus-leukemia effect, which could be essentially

64 r immune reconstitution and a quite powerful graft-versus-leukemia effect with a low incidence of gra

65 ne response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-

66 This approach permits us to explore the graft-versus-leukemia effect without the toxicity of mye